ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 811

The Presence of Giant Cells in the Temporal Artery Biopsy Is Associated with Reduced Risk of Future Large Vessel Involvement in Patients with Biopsy-Proven Giant Cell Arteritis

Nazanin Naderi1,2, Aladdin Mohammad3,4,5, Minna Willim4,6, Jan-Åke Nilsson1,6 and Carl Turesson1,6, 1Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2Department of Rheumatology, Danderyd Hospital, Stockholm, Sweden, 3Department of Renal Medicine, Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, 4Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, 5Department of Rheumatology, Skåne University Hospital, Lund, Sweden, 6Department of Rheumatology, Skåne University Hospital, Malmö, Sweden

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: biopsies, giant cell arteritis and large vessel vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is a systemic disease with extensive vascular involvement. The mechanisms underlying the diversity of GCA phenotypes are incompletely understood. The purpose of this study was to investigate predictors of large vessel involvement (LVI) in a population based cohort of patients with GCA.

Methods: Patients with biopsy-proven GCA were identified using a regional pathology register. Patients with positive temporal artery biopsies (TAB) performed between 1997 and 2010 who were diagnosed with GCA in two defined areas of the region were included. A structured review of histopathology reports and case records through July 2016 of all the identified patients was performed. Reports of all relevant radiological and clinico-physiological studies were reviewed, and cases with LVI were identified according to a pre-specified protocol. LVI was defined as aneurysm, ectasia or stenosis of the aorta or its main branches. Patients were censored at the date of first LVI, death, migration from the area or July 29, 2016. Event free survival was estimated using the Kaplan-Meier method. Potential predictors of LVI were also examined using Cox regression models.

Results: A total of 274 patients with biopsy-proven GCA (77 % women) were included. The mean age at GCA onset was 75.7 years (standard deviation (SD) 8.1). Fifty-one patients (19 %) had documented LVI during the follow-up. The median time from diagnosis of GCA to detection of LVI was 4.5 years (interquartile range 0.6-7.4). There were 32 patients with aortic involvement (63% of those with LVI; 12 % of all GCA cases). LVI occurred to a similar extent in women and men (75th percentile of LVI-free survival 12.9 and 13.1 years, respectively; p=0.96). Survival free of LVI was significantly longer in patients with giant cells present in the TAB (75th percentile 13.7 vs 6.7 years; p=0.014). There was a trend towards reduced risk of LVI with increasing age at GCA diagnosis (hazard ratio (HR) 0.81 per SD; 95 % confidence interval 0.61-1.08). Other histopathology features, visual symptoms, platelet count, CRP, ESR or symptoms of polymyalgia rheumatica had no significant impact on the risk of LVI. In age-adjusted analysis, the presence of giant cells in the TAB was associated with a reduced risk of LVI (HR 0.48; 95 % CI 0.27-0.86).

Conclusion:

Clinical features of GCA had no major impact on the risk of LVI. However, the negative association with giant cells in the biopsy suggests that patients with LVI constitute a subset of GCA with particular disease mechanisms.


Disclosure: N. Naderi, None; A. Mohammad, None; M. Willim, None; J. Å. Nilsson, None; C. Turesson, None.

To cite this abstract in AMA style:

Naderi N, Mohammad A, Willim M, Nilsson JÅ, Turesson C. The Presence of Giant Cells in the Temporal Artery Biopsy Is Associated with Reduced Risk of Future Large Vessel Involvement in Patients with Biopsy-Proven Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-presence-of-giant-cells-in-the-temporal-artery-biopsy-is-associated-with-reduced-risk-of-future-large-vessel-involvement-in-patients-with-biopsy-proven-giant-cell-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-presence-of-giant-cells-in-the-temporal-artery-biopsy-is-associated-with-reduced-risk-of-future-large-vessel-involvement-in-patients-with-biopsy-proven-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology